



Figure S1. Loss of *Tgm3* leads to an increased IL-22 and IL-17A release upon imiquimod treatment. IL22 and IL17-A immunostaining in imiquimod treated wild-type, *Tgm2^{-/-}* and *Tgm3^{-/-}* mice skin samples confirmed inflammation induction *in vivo* and the increased effect of imiquimod on *Tgm3^{-/-}* skin. One representative staining image/group is shown.

Figure S1 - Piro *et al*